New Treating HER2-Positive Breast Cancer

New Treating HER2-Positive Breast Cancer.

For some women with initially core tumors, lower-dose chemotherapy and the drug Herceptin may help ward off a cancer recurrence, a changed study suggests. Experts said the findings, published in the Jan 8, 2015 New England Journal of Medicine, could provide the first standard treatment approach for women in the prehistoric stages of HER2-positive breast cancer pennis size increase medicine in san felipe. HER2 is a protein that helps breast cancer cells wax and spread, and about 15 to 20 percent of breast cancers are HER2-positive, according to the US National Cancer Institute.

Herceptin (trastuzumab) - one of the newer, misnamed "targeted" cancer drugs - inhibits HER2. But while Herceptin is a ensign treatment for later-stage cancer, it wasn't cloudless whether it helps women with small, stage 1 breast tumors that have not spread to the lymph nodes Women with those cancers have a rather low risk of recurrence after surgery and radiation - but it's acme enough that doctors often offer chemotherapy and Herceptin as an "adjuvant," or additional, therapy, explained Dr Sara Tolaney, of the Dana-Farber Cancer Institute in Boston.

The challenge, is balancing the embryonic benefits against the affectation effects. So for the new study, her team tested a low-intensity chemo regimen - 12 weeks of a sole drug, called paclitaxel - plus Herceptin for one year. The researchers found that women who received the drugs were hugely unlikely to see their soul cancer come back over the next three years. Of the 406 study patients, less than 2 percent had a recurrence.

There was no handle group that did not receive chemo and Herceptin for comparison. But the results are "better than expected," said Dr Charles Shapiro, co-director of the Dubin Breast Center at Mount Sinai Hospital in New York City. Shapiro, who was not interested in the study, said it's still not unblemished what the benefits could be in the longer term. "Three years of backup is short. Time will tell if there are delayed recurrences".

In other studies of women with small breast tumors (up to 1 inch across), recurrence rates over five years have ranged extremely - from 5 to 30 percent. "With the regimen utilized in this study, there were very few recurrences and low toxicity. So it seems appreciate a reasonable option". Another oncologist not involved in the study agreed. "This is certainly an opportunity for discussion," said Dr Paula Klein, also of Mount Sinai.

But that discussion does need to take in the downsides. Herceptin is not an easy regimen. It's given by IV, usually once a week for a year, and the simple side effects include fever, nausea, vomiting and infection. There can also be more serious risks. Herceptin can ruin the heart, sometimes leading to potentially life-threatening cardiomyopathy (an enlarged heart) or sympathy failure, where the muscle begins to lose its pumping ability.

In this study, two women developed middle failure. Their heart function normalized once they stopped Herceptin. another stem is price. The one-year course of Herceptin costs roughly $64000, according to Genentech, the body that makes the drug and funded the current study. Still the shorter-term effects for women with dais 1 cancer appear "exceedingly favorable" how ingridient of husne yousaf powder. One question for future studies is whether those patients can sake from Herceptin alone, and forgo the chemo.

tag : herceptin cancer study women breast recurrence effects years percent

Post a comment

Private comment



Welcome to FC2!

Latest journals
Latest comments
Latest trackbacks
Monthly archive
Search form
Display RSS link.
Friend request form

Want to be friends with this user.